Sign in to see private stats on your profile page — or add photo, interests, videos, mentoring, etc.

    Michele Tana, MD

    TitleAssistant Professor
    SchoolUCSF School of Medicine
    DepartmentMedicine
    Address1001 Potrero Avenue 3D
    San Francisco CA 94110
    vCardDownload vCard

      Collapse Biography 
      Collapse Education and Training
      Harvard CollegeA.B.Classics2000
      Harvard UniversityM.D.Medical Schoool2005
      Stanford UniversityInternal MedicineSchool of Medicine2008
      California Pacific Medical CenterGastroenterologyDepartment of Medicine2011
      National Institutes of HealthHepatologyNIDDK2013

      Collapse Overview 
      Collapse Overview
      Michele Tana grew up in Northern Virginia. She studied the Classics at Harvard College, then went to Harvard Medical School. She did her Internal Medicine training at Stanford University Hospital and Clinics and her gastroenterology fellowship at California Pacific Medical Center. She spent two years at the National Institutes of Health as a Clinical Fellow in the National Institute of Diabetes and Digestive and Kidney Diseases, Liver Diseases Branch, then joined the UCSF faculty at San Francisco General Hospital in 2013. She is a clinician-educator with an interest in clinical research.

      Collapse Interests
      alcoholic liver disease, autoimmune hepatitis, fatty liver disease, gastrointestinal endoscopy, health disparities, health services research, medical education, mentoring, patient reported outcomes, primary biliary cirrhosis, underserved populations, viral hepatitis

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Ha J, Yan M, Aguilar M, Bhuket T, Tana MM, Liu B, Gish RG, Wong RJ. Race/ethnicity-specific disparities in cancer incidence, burden of disease, and overall survival among patients with hepatocellular carcinoma in the United States. Cancer. 2016 Aug 15; 122(16):2512-23. PMID: 27195481.
        View in: PubMed
      2. Ha J, Yan M, Aguilar M, Tana M, Liu B, Frenette CT, Bhuket T, Wong RJ. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies. J Clin Gastroenterol. 2016 May-Jun; 50(5):423-30. PMID: 26583267.
        View in: PubMed
      3. Tana MM, Shums Z, Milo J, Norman GL, Leung PS, Gershwin ME, Noureddin M, Kleiner DE, Zhao X, Heller T, Hoofnagle JH. The Significance of Autoantibody Changes Over Time in Primary Biliary Cirrhosis. Am J Clin Pathol. 2015 Oct; 144(4):601-6. PMID: 26386081.
        View in: PubMed
      4. Tana MM, Zhao X, Bradshaw A, Moon MS, Page S, Turner T, Rivera E, Kleiner DE, Heller T. Factors associated with the platelet count in patients with chronic hepatitis C. Thromb Res. 2015 May; 135(5):823-8. PMID: 25728497; PMCID: PMC4414791 [Available on 05/01/16].
      5. Tana MM, Heller T. Autoantibodies in hepatitis C: red flag or bystander effect? J Pediatr Gastroenterol Nutr. 2013 Mar; 56(3):243. PMID: 23443062; PMCID: PMC3584299.
      6. Tana MM, Hoofnagle JH. Scar undone: long-term therapy of hepatitis B. Lancet. 2013 Feb 9; 381(9865):433-4. PMID: 23234726.
        View in: PubMed
      Michele's Networks
      Related Concepts
      Derived automatically from this person's publications.
      _
      Related Authors
      People who share related concepts with this person.
      _
      Back to TOP